PI-1840Chymotrypsin-like (CT-L) inhibitor CAS# 1401223-22-0 |
- BYL-719
Catalog No.:BCC3707
CAS No.:1217486-61-7
- VS-5584 (SB2343)
Catalog No.:BCC2047
CAS No.:1246560-33-7
- HS-173
Catalog No.:BCC5363
CAS No.:1276110-06-5
- CAL-101 (Idelalisib, GS-1101)
Catalog No.:BCC1270
CAS No.:870281-82-6
- XL147
Catalog No.:BCC2487
CAS No.:956958-53-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1401223-22-0 | SDF | Download SDF |
PubChem ID | 56945245 | Appearance | Powder |
Formula | C22H26N4O3 | M.Wt | 394.47 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | H2O : < 0.1 mg/mL (insoluble) | ||
Chemical Name | N-propan-2-yl-2-(4-propylphenoxy)-N-[(3-pyridin-3-yl-1,2,4-oxadiazol-5-yl)methyl]acetamide | ||
SMILES | CCCC1=CC=C(C=C1)OCC(=O)N(CC2=NC(=NO2)C3=CN=CC=C3)C(C)C | ||
Standard InChIKey | ZVVXAODXPVWGMF-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C22H26N4O3/c1-4-6-17-8-10-19(11-9-17)28-15-21(27)26(16(2)3)14-20-24-22(25-29-20)18-7-5-12-23-13-18/h5,7-13,16H,4,6,14-15H2,1-3H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | PI-1840 is a reversible and selective inhibitor of chymotrypsin-like (CT-L) with IC50 value of 27 nM. | |||||
Targets | CT-L | |||||
IC50 | 27 nM |
PI-1840 Dilution Calculator
PI-1840 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.535 mL | 12.6752 mL | 25.3505 mL | 50.7009 mL | 63.3762 mL |
5 mM | 0.507 mL | 2.535 mL | 5.0701 mL | 10.1402 mL | 12.6752 mL |
10 mM | 0.2535 mL | 1.2675 mL | 2.535 mL | 5.0701 mL | 6.3376 mL |
50 mM | 0.0507 mL | 0.2535 mL | 0.507 mL | 1.014 mL | 1.2675 mL |
100 mM | 0.0254 mL | 0.1268 mL | 0.2535 mL | 0.507 mL | 0.6338 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
PI-1840 is a potent and selective inhibitor of proteasome with IC50 value of 27 nM for chymotrypsinlike (CT-L) activity [1].
The 26S proteasome consists of a 19S regulatory particle (RP) and a 20S core particle. The 26S proteasome have three main catalytic activities: chymotrypsin-like (CT-L), peptidylglutamyl peptide hydrolyzing-like (PGPH-L) and trypsin-like (T-L) activities. CT-L activity plays an important role in the degradation of tumor suppressor and apoptotic proteins [1].
PI-1840 is a rapidly reversible and non-covalent proteasome CT-L inhibitor. PI-1840 exhibited excellent selectivity for CT-L over PGPH-L and T-L activities. In MDA-MB-468 human breast cancer cells, PI-1840 inhibited the CT-L activity with IC50 value of 0.37 μM and inhibited cell survival/proliferation [1]. Also, PI-1840 exhibited 121-fold selectivity for the constitutive 20 S proteasome over the immunoproteasome with IC50 values of 18 and 2170 nM, respectively. In MDA-MB-468 cells, PI-1840 caused the accumulation of CT-L substrates IκB-α, p27 and Bax. Also, PI-1840 reduced the levels of survivin, p-Akt and Ser(P)-6 and induced apoptosis through poly(ADP-ribose) polymerase cleavage and caspase-3 activation [2].
In nude mice bearing human breast tumor, PI-1840 (150 mg/kg/day, i.p, daily) inhibited tumor growth by 85% [2].
References:
[1]. Ozcan S, Kazi A, Marsilio F, et al. Oxadiazole-isopropylamides as potent and noncovalent proteasome inhibitors. J Med Chem, 2013, 56(10): 3783-3805.
[2]. Kazi A, Ozcan S, Tecleab A, et al. Discovery of PI-1840, a novel noncovalent and rapidly reversible proteasome inhibitor with anti-tumor activity. J Biol Chem, 2014, 289(17): 11906-11915.
- 3'-Hydroxygynuramide II
Catalog No.:BCC8634
CAS No.:1401093-57-9
- AMG 925
Catalog No.:BCC5150
CAS No.:1401033-86-0
- Tannic acid
Catalog No.:BCN2643
CAS No.:1401-55-4
- 3-CPMT
Catalog No.:BCC6845
CAS No.:14008-79-8
- PB-22
Catalog No.:BCC1840
CAS No.:1400742-17-7
- Eucalyptin acetate
Catalog No.:BCN6216
CAS No.:14004-35-4
- 4μ8C
Catalog No.:BCC4754
CAS No.:14003-96-4
- Nystatin (Fungicidin)
Catalog No.:BCC4813
CAS No.:1400-61-9
- Dimethylolurea
Catalog No.:BCC8943
CAS No.:140-95-4
- 4-Allylanisole
Catalog No.:BCC8674
CAS No.:140-67-0
- Pentamidine isethionate
Catalog No.:BCC5644
CAS No.:140-64-7
- Nithiamide
Catalog No.:BCC4687
CAS No.:140-40-9
- ML 277
Catalog No.:BCC7976
CAS No.:1401242-74-7
- 15,16-Dihydroxyoctadeca-9Z,12Z-dienoic acid
Catalog No.:BCC8438
CAS No.:140129-22-2
- Pterisolic acid A
Catalog No.:BCN4842
CAS No.:1401419-85-9
- Pterisolic acid B
Catalog No.:BCN4843
CAS No.:1401419-86-0
- Pterisolic acid C
Catalog No.:BCN4838
CAS No.:1401419-87-1
- Pterisolic acid D
Catalog No.:BCN4839
CAS No.:1401419-88-2
- Pterisolic acid E
Catalog No.:BCN4841
CAS No.:1401419-89-3
- Pterisolic acid F
Catalog No.:BCN4840
CAS No.:1401419-90-6
- Epimedin A1
Catalog No.:BCN5935
CAS No.:140147-77-9
- ATPA
Catalog No.:BCC6940
CAS No.:140158-50-5
- Negundonorin A
Catalog No.:BCN7150
CAS No.:1401618-51-6
- (-)-Praeruptorin A
Catalog No.:BCN7664
CAS No.:14017-71-1
Discovery of PI-1840, a novel noncovalent and rapidly reversible proteasome inhibitor with anti-tumor activity.[Pubmed:24570003]
J Biol Chem. 2014 Apr 25;289(17):11906-15.
The proteasome inhibitor bortezomib is effective in hematologic malignancies such as multiple myeloma but has little activity against solid tumors, acts covalently, and is associated with undesired side effects. Therefore, noncovalent inhibitors that are less toxic and more effective against solid tumors are desirable. Structure activity relationship studies led to the discovery of PI-1840, a potent and selective inhibitor for chymotrypsin-like (CT-L) (IC50 value = 27 +/- 0.14 nm) over trypsin-like and peptidylglutamyl peptide hydrolyzing (IC50 values >100 mum) activities of the proteasome. Furthermore, PI-1840 is over 100-fold more selective for the constitutive proteasome over the immunoproteasome. Mass spectrometry and dialysis studies demonstrate that PI-1840 is a noncovalent and rapidly reversible CT-L inhibitor. In intact cancer cells, PI-1840 inhibits CT-L activity, induces the accumulation of proteasome substrates p27, Bax, and IkappaB-alpha, inhibits survival pathways and viability, and induces apoptosis. Furthermore, PI-1840 sensitizes human cancer cells to the mdm2/p53 disruptor, nutlin, and to the pan-Bcl-2 antagonist BH3-M6. Finally, in vivo, PI-1840 but not bortezomib suppresses the growth in nude mice of human breast tumor xenografts. These results warrant further evaluation of a noncovalent and rapidly reversible proteasome inhibitor as potential anticancer agents against solid tumors.